{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:27:49Z","timestamp":1772051269782,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T00:00:00Z","timestamp":1425081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12883-015-0267-7","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T09:16:06Z","timestamp":1425028566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson\u2019s disease: an open-label study"],"prefix":"10.1186","volume":"15","author":[{"given":"Jong-Min","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Ju","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom Seok","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritibha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Thierfelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Asia Pacific Rotigotine Add-on Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,28]]},"reference":[{"key":"267_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448\u201358.","journal-title":"Mov Disord"},{"issue":"Suppl 11","key":"267_CR2","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005;20 Suppl 11:S11\u20136.","journal-title":"Mov Disord"},{"key":"267_CR3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","volume":"28","author":"T Kvernmo","year":"2006","unstructured":"Kvernmo T, H\u00e4rtter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28:1065\u201378.","journal-title":"Clin Ther"},{"key":"267_CR4","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00702-003-0081-z","volume":"110","author":"H Reichmann","year":"2003","unstructured":"Reichmann H, Herting B, M\u00efller A, Sommer U. Switching and combining dopamine agonists. J Neural Transm. 2003;110:1393\u2013400.","journal-title":"J Neural Transm"},{"issue":"Suppl 6","key":"267_CR5","first-page":"VI\/19","volume":"251","author":"S Junghanns","year":"2004","unstructured":"Junghanns S, Gl\u00f6ckler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol. 2004;251 Suppl 6:VI\/19\u201323.","journal-title":"J Neurol"},{"key":"267_CR6","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s00415-003-1086-0","volume":"250","author":"F Stocchi","year":"2003","unstructured":"Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S. Dual dopamine agonist treatment in Parkinson's disease. J Neurol. 2003;250:822\u20136.","journal-title":"J Neurol"},{"key":"267_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","volume":"379","author":"D Scheller","year":"2009","unstructured":"Scheller D, Ullmer C, Berkels R, Gwarek M, L\u00fcbbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009;379:73\u201386.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"267_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.clinthera.2012.02.008","volume":"34","author":"JP Elshoff","year":"2012","unstructured":"Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther. 2012;34:966\u201378.","journal-title":"Clin Ther"},{"key":"267_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","volume":"128","author":"MJ Millan","year":"2010","unstructured":"Millan MJ. From the cell to the clinic: a comparative review of the partial D(2)\/D(3)receptor agonist and alpha2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacol Ther. 2010;128:229\u201373.","journal-title":"Pharmacol Ther"},{"key":"267_CR10","first-page":"701","volume":"57","author":"K Radad","year":"2005","unstructured":"Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep. 2005;57:701\u201312.","journal-title":"Pharmacol Rep"},{"key":"267_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/mds.870090613","volume":"9","author":"RJ Vermeulen","year":"1994","unstructured":"Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Wolters EC, Stoof JC. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov Disord. 1994;9:664\u201372.","journal-title":"Mov Disord"},{"key":"267_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6:513\u201320.","journal-title":"Lancet Neurol"},{"key":"267_CR13","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","volume":"68","author":"PA LeWitt","year":"2007","unstructured":"LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68:1262\u20137.","journal-title":"Neurology"},{"key":"267_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90\u20139.","journal-title":"Mov Disord"},{"key":"267_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","volume":"77","author":"AH Schapira","year":"2011","unstructured":"Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77:767\u201374.","journal-title":"Neurology"},{"key":"267_CR16","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/mds.23498","volume":"26","author":"F Stocchi","year":"2011","unstructured":"Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord. 2011;26:1259\u201365.","journal-title":"Mov Disord"},{"key":"267_CR17","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.21741","volume":"22","author":"N Giladi","year":"2007","unstructured":"Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22:2398\u2013404.","journal-title":"Mov Disord"},{"key":"267_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2165\/00002018-200326060-00005","volume":"26","author":"M Etminan","year":"2003","unstructured":"Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf. 2003;26:439\u201344.","journal-title":"Drug Saf"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-015-0267-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0267-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0267-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0267-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T09:02:38Z","timestamp":1630573358000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-015-0267-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,28]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1186\/s12883-015-0267-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,28]]},"assertion":[{"value":"29 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"17"}}